Drug Utilization Review (DUR) Meeting Minutes
December 4, 2019

Members Present: Andrea Honeyman, Katie Kram, Tanya Schmidt, Jennifer Iverson, Gabriela Balf, Laura Schield, Jennifer Iverson, Mary Aaland

Medicaid Pharmacy Department: Alexi Murphy

Announcements
The North Dakota Medicaid DUR Board held an election for the open DUR Board Chair position at the start of the meeting. A. Honeyman was nominated and K. Kram made a motion to close the nomination proceedings with no voiced opposition. A voice vote was called with A. Honeyman elected as the DUR Board Chair by unanimous vote of the present DUR Board members.

Old Business
Chair A. Honeyman called the meeting to order at 1:20 p.m. Chair A. Honeyman asked for a motion to approve the minutes of the September meeting. T. Schmidt moved that the minutes be approved, and L. Schield seconded the motion. The chair called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Review Top 25 Drugs
T. DeRuiter and A. Murphy presented the quarterly review of the top 25 drugs based on total cost od claims, as well as the top 25 drugs based on the total number of claims for the 2nd quarter of 2019.

PDL/PA Criteria Updates
A. Murphy shared with the Board all of changes made to the Preferred Drug List since the most recent version of the Preferred Drug List was posted. Notable changes included removing PA requirements for asrmodafinil, and the pulmonary hypertension agents Orenitram ER, Treprostinil, Tyvaso, and Uptravi, as well as adding numerous agents to recently DUR Board approved PA class criteria. When a new version of the PDL is published and posted to the website, all updates/changes made since the last version are called out at the top of the document itself.

Second Review of Antifungal Agents for Aspergillus and Candidiasis Infections
A motion and second was made at the September meeting to place select antifungal agents for the treatment of aspergillus and candidiasis infections on prior authorization. The topic was brought up for a second review. K. Kram made a motion to amend the criteria to (a). allow approval in cases where documentation is provided showing preferred agents cannot be used; and (b). change the approval duration to “Per label recommendations”. A. Honeyman seconded the motion. There was no public comment. Chair A. Honeyman called for a voice vote on the motion to amend the criteria and the motion passed with no audible dissent. Chair A. Honeyman then called for a voice vote on approving the amended criteria, which passed with no audible dissent.

Second Review of Eosinophilic Asthma Agents
A motion and second was previously made to place agents for the treatment of eosinophilic asthma on prior authorization. The topic was brought up for a second review. During public comments, Kevin Duhrkopf of Sanofi Genzyme spoke regarding the use of Dupixent and it's role in therapy. K. Kram made a motion to amend the criteria by removing requirements for baseline eosinophil levels and/or corticosteroid dependent asthma. L. Schield seconded the motion. Chair A. Honeyman called for a voice vote on the motion to amend the criteria and the motion passed with no audible dissent. Chair A. Honeyman then called for a voice vote on approving the amended criteria, which passed with no audible dissent.

Annual Review of Prior Authorization Forms and Criteria
The Board reviewed all forms and criteria utilized for all medications that are currently placed on prior authorization. A. Murphy explained how all prior authorization criteria will be moving to a single Preferred Drug List (PDL) document starting on 01/01/2020, which should simplify the process of locating criteria. A. Murphy specifically highlighted updates to the long-acting opioid analgesic criteria, that smoking cessation agents and preferred opioid dependence agents will no longer require prior authorization, and changes to criteria in some inhaler agents. She further discussed the continued consolidation of multiple request forms to the "General" prior authorization request form, as well as the consolidation of all opioid request forms to a single form. The Board recommended the following changes to the prior authorization forms: rearranging questions on the hepatitis C treatment agents form; removing the outdated language of a 30-day requirement language from the hyperkalemia form and adding language for chronic hyperkalemia; and correcting formatting/wording on the Orilissa and Insulin PA forms. A motion was made by K. Kram to approve the reviewed forms with the recommended changes, which was seconded by L. Schield. Chair A. Honeyman then called for a voice vote for approval of the reviewed forms and criteria, which passed with no audible dissent.

New Business
Review of Glucagon Agents
T. DeRuiter and A. Murphy presented a review of glucagon agents to the Board. A motion was made by T. Schmidt to manage these medications through prior authorization. The motion was seconded by L. Schield. This topic will be reviewed at the next meeting.

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. K. Kram moved to approve the new criteria and A. Honeyman seconded the motion. The motion passed with no audible dissent.

Adjournment and Upcoming Meeting Date
Chair A. Honeyman adjourned the meeting at 2:45 pm. The next DUR Board meeting will be held March 4, 2020 at 1:00 pm at the State Capitol building in the Brynhild -Haugland room.